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Objective: Amphiregulin (AREG) and Fractalkine (FRACT), are involved in a variety of normal and path-
ological processes, and are both suggested to be relevant to joint degeneration. The aims of the present
study included (1) testing association between circulating levels of these biomarkers and joint pathol-
ogies, (2) evaluation of the putative genetic and familial factors’ effect on AREG and FRACT variability.
Design: The study was conducted in the family-based sample of 923 Caucasian individuals. Variance
component analysis was used to assess contribution of genetic and environmental factors to variability of
AREG and FRACT concentration.
Results: The mean levels of FRACT were signiﬁcantly higher in the affected group with arthropathies
(synovial joints osteoarthritis (OA) and disc degenerative disease, DDD) then in the control group
(P< 0.0004). Circulating AREG levels were higher in DDD (P¼ 0.0272). Genetic factors constituted the
main source of the interindividual differences of the AREG and FRACT levels in our sample, and explained
29.68% and 41.68% of the total variation, respectively. The phenotypic correlation between AREG and
FRACT was substantial (r¼ 0.55, P¼ 0.0001) and was associated with both common genetic and envi-
ronmental factors. Speciﬁcally, 30% of the phenotypic correlation between AREG and FRACT was due to
common genetic effects.
Conclusions: Further studies are required to assess relevancy of FRACT to clinical diagnosis and prognosis
of arthropathies, to investigate the mechanisms behind the observed phenotypic and genetic covariation
among the studied biomarkers, and to explore speciﬁc genetic polymorphisms affecting AREG and FRACT
variation.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Epidermal growth factors (EGF) are important in cellular
growth, proliferation, and cellular differentiation, and typically act
in an autocrine and paracrine manner on their speciﬁc cell
membrane receptors1. Amphiregulin (AREG) is a member of the
EGF family. It binds and activates the epidermal growth factor
receptor (EGFR), resulting in dimerization of the receptor, auto-
phosphorylation, and tyrosine phosphorylation of downstream
proteins2. AREG has stimulatory effect on various cell types,
including several human ﬁbroblast cell lines, while being inhibitory
to some neuroblastoma and adenocarcinoma cell lines3. EGFR and. Livshits, Human Population
nthropology, Sackler Faculty
Israel. Tel: 972-3-640-9494;
s Research Society International. PAREG over-expression has been observed in epidermal hyper-
plasia4 and several human cancers, including liver5 and breast
cancer3. Experimental data show that AREG participates in a variety
of physiological processes, such as bone formation6 and nerve
regeneration7. Recent studies also related AREG to joint disorders.
For example, one study indicated that AREG protein concentration
was signiﬁcantly increased in rheumatoid arthritis (RA) synovial
ﬂuid and was higher than that in osteoarthritis (OA) synovial ﬂuid8.
Of the seven examined EGF-like ligands only AREG was over-
expressed in tissues from the RA patients. Another study reported
that AREG-growth factor receptor signaling was highly activated in
synovial cells isolated from RA patients9. These and other ﬁndings
suggest that AREG functions include stimulation of synovial cells
and that elevated levels of AREG may be involved in the patho-
genesis of RA.
Complex signaling pathways involving growth factors function
through and are modulated by equally complex networks of other
biologically active factors like cytokines. Thus, for example, coor-
dinated functioning of various growth factors and cytokines duringublished by Elsevier Ltd. All rights reserved.
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rientos et al.2 One therefore may expect that cytokines, speciﬁcally
chemokines, may also play roles in functioning of EGFs in general
and of AREG in particular.
Indeed, it has been shown that fractalkine (FRACT),
a membrane-bound chemokine, is involved in the development
of numerous inﬂammatory pathologies including RA10 and
malignancies11. Of special interest in this context is the recent
study that showed that EGFR signaling pathways mediate
important anti-apoptotic and proliferative effects of FRACT12.
FRACT is the only member of the so called CX3C family of the
soluble chemotactic cytokines11. Similarly to other chemokines,
such as monocyte chemotactic protein-1 (MCP-1; the member of
the CC family of the chemokines), it has a wide range of functional
roles that contribute to health maintenance and inﬂammation
diseases. There are studies suggesting that FRACT is signiﬁcantly
elevated in RA synovial ﬂuid compared with synovial ﬂuid from
patients with OA or other forms of arthropathies13. Notably,
elevated serum MCP-1 concentrations were found in active
juvenile RA patients and modulation of MCP-1 signaling in
experimental RA showed beneﬁcial effects on inﬂammation and
joint destruction14.
It appears therefore that circulating levels of AREG, FRACT, EGFR,
and MCP-1 maybe interrelated due to possible common metabolic
pathways. We and others examined previously contribution of the
genetic andotherpotential confounding factorsonvariationofMCP-
1 and EGFR15,16. However, we found no published data on pheno-
typic links amongAREG, FRACT, EGFR, andMCP-1 andnodata on the
contribution of the genetic factors to AREG and FRACT variation.We
address these and other questions in the present study, using a large
family-based sample of apparently healthy Caucasian individuals.
Speciﬁcally, the main aims of the present study included (1) testing
association between circulating levels of these biomarkers and joint
degeneration, (2) evaluation of the putative genetic and familial
factors’ effect on AREG and FRACT variability.
Materials and methods
Sample
The population examined in the present study were Chuva-
shians (Caucasians, living along Volga river, Russia) repeatedly
described by us elsewhere17,18. In total 923 individuals were avail-
able for the present study. Of these, circulating levels of AREG and
FRACT were assayed in 914 and 923 individuals, respectively, which
correspondingly included 204 and 200 marital couples, 833 and
814 parenteoffspring pairs, and 261 sib pairs (Supplementary
Fig. S1). The following data were collected for each participating
individual: gender, age, blood samples, hand radiographs, standard
anthropometrical measurements, as well as data on chronic
morbidity and medical treatment obtained from participants’
medical records. Reading and interpreting the medical record data,
as well as interviewing study participants regarding their health
status, were carried out by an experienced clinician, who corrob-
orated the diagnoses from the medical records and veriﬁed them
against the international nomenclature. Vague conditions were not
included. Participants were free from serious chronic and/or acute
illnesses. However, some of the individuals had clinically diagnosed
arthropathies. Speciﬁcally, the sample included 57 individuals with
diagnosed arthritis in synovial joint, i.e., OA, of shoulder, hand, knee
or their combination, and 130 individuals had symptoms of disc
degenerative disease (DDD) of spine. Clinical severity of each
chronic condition was not deﬁned in the patient ﬁles. The study
was conducted in agreement with the declaration of Helsinki and
with the approval of the Tel-Aviv University Ethics Committee.Biochemical measurements
Venous blood samples were taken after an overnight fast.
Within 1 h of collection, samples were centrifuged to obtain
plasma, frozen in aliquots, and stored at 80C until analyzed. The
AREG and FRACT levels were measured by sandwich Enzyme-
linked immunosorbent assay (ELISA) using DuoSet ELISA develop-
ment KIT (R&D Systems Minneapolis, MN, USA). The unbound
antibodies were washed and blocked with bovine serum albumin
(BSA) in phosphate buffered saline (PBS). Standard and plasma
samples were added to the wells and the plate was incubated for
2 h at room temperature. The plate was washed, and 100 mL of
detecting biotinylated goat anti-human antibody was added to
each well, and again the plate was incubated for 2 h at room
temperature. After this, the plate was washed and 100 mL of
peroxidase conjugated streptavidin was added, and the incubation
continued for another 20 min at room temperature. After the plate
was washed again, 100 mL of substrate solution was added. The
reaction was terminated by adding 50 mL stop solution (H2SO4).
Then the absorbance values weremeasured immediately at 450 nm
and with a correction of 540 nm by using a microplate reader
(Elx808, Bio-Tek Instruments, USA). All the observed measure-
ments were above the minimal detection sensitivity (6.5 pg/ml for
AREG, and 63.0 pg/ml for FRACT). The inter- and intra-assay coef-
ﬁcients of variation in our analyses were as follows: 6.8% and 4.5%
for AREG, and 6.3% and 3.5% for FRACT. In addition, we examined
data on MCP-1 and EGFR concentrations used in our previous
publications15,16, and measured in all the above individuals.
Statistical analysis
Prior to quantitative genetic analysis the data were subjected to
preliminary statistical analysis, which included descriptive statis-
tics and selection of the potential covariates. These tasks were
carried out using the STATISTICA 7.1 package19. Familial composi-
tion of the sample was accounted for in the adjustment procedure
of the primary phenotypes for covariates. The latter and all the
following analyses were conducted using MAN-2009 package20.
Next, we applied variance components analysis to assess
magnitude and relative importance of the genetic and various
familial effects on AREG and FRACT plasma levels variability21. This
method allows partitioning the total variability of the phenotype
(VTOT) into major contributing factors: additive genetic component
(VAD), common spouse environment component (VSP), common
household environment component (VHS) and common siblings’
environment (VSIB). The residual variance component correspond-
ing to the portion of the phenotype’s variability not explained by
the model is referred to as VRS. Furthermore, the method permits
simultaneous modeling of the covariates effects (such as gender,
age, and speciﬁc genetic polymorphisms). A maximum likelihood
ratio test (LRT) was used as a ﬁtting technique to compare the ﬁts of
the general model and more limited nested models, containing
reduced number of parameters. After excluding all statistically non-
signiﬁcant parameters from the general model, a best ﬁtting and
most parsimonious model (MPM) was obtained.
Since the study biomarkers showed statistically signiﬁcant pair-
wise correlations, we also undertook bivariate variance component
analysis to determine to what extent common genetic and shared
environmental factors caused the observed correlations. MAN
program20, based on quantitative genetic theory21, computes the
variance components for each pair of traits and evaluates the addi-
tive genetic (RAD) and environmental (RRS) correlation between
them. Statistically signiﬁcant correlation between genetic factors
and/or between environmental factors suggests that the same genes
or the same environment (or both) inﬂuences both traits. The genetic
Table I
Descriptive statistics of AREG (ng/ml) and FRACT (ng/ml) plasma levels in the study
sample
Sample N Mean Median Min Max SD
AREG all 914 34.604 21.561 6.134 254.860 30.586
AREG men 468 33.162 20.988 6.808 163.188 28.587
AREG women 446 36.117 21.648 6.134 254.860 32.516
FRACT all 923 2136.545 1204.900 63.090 30203.000 3516.210
FRACT men 471 1953.609 1077.310 63.090 30203.000 3384.360
FRACT women 452 2327.171 1326.947 172.990 28725.080 3642.520
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amount of overlap between the genes (environmental factors)
inﬂuencing those traits. The magnitude of the genetic correlation
between traits corresponds to the degree of pleiotropy, and RAD¼ 1
indicates that the two sets of genes overlap completely. Evidence of
pleiotropy is indicated by a genetic correlation signiﬁcantly different
from zero22. The implementation of this method in our sample was
repeatedly described by our team elsewhere22,23.
Results
Preliminary statistics for biochemical markers
Thedescriptive statistics forAREGandFRACTplasma levels for the
whole sample and according to sex are presented in Table I. The
descriptive statistics for MCP-1 and EGFR were published else-
where15,16, and therefore are not reported here. The mean levels of
FRACT were statistically signiﬁcantly higher in women than in men
(ManneWhitney U test, P< 0.0001). On the other hand, no statisti-
cally signiﬁcantsexeffectswere seen inAREG(ManneWhitneyU test,
P¼ 0.161). No signiﬁcant correlations between age and either AREG
or FRACT levels were observed. The distributions of the measured
biochemical markers showed statistically signiﬁcant deviation from
normality. Consequently all subsequent analyses were carried out
using the log-transformed and standardized phenotypes.
Using standard analysis of variance (ANOVA), we comparedmean
circulating levels of AREG and FRACT among the individuals with
diagnosed arthropathies and control (Fig. 1). Speciﬁcally, for each
biomarker we tested the equality of plasma levels in controls
(N¼ 736) vs (1) individuals with diagnosed OA (N¼ 57), (2)Fig. 1. Bar plot of mean circulating levels of AREG and FRACT among the individuals
with diagnosed arthropathies and in the control group. Mean values and their
respective standard errors are presented. The data were log-transformed and stan-
dardized prior to comparison. N ("Not Affected")¼ 736, N ("OA of Synovial Joints")¼
57, N ("Disc Degenerative Disease")¼ 130, N ("All Arthropathies")¼ 187. The data on
circulating levels of each of the biomarkers, AREG and FRACT, were log-transformed to
achieve normality of the distribution, and thenwere standardized for the sample mean
(z-standardization).individuals with diagnosed DDD (N¼ 130), and (3) the combined
group of affected individuals (N¼ 187). Compared to controls, FRACT
concentrations on average were consistently higher in affected indi-
viduals: OA group (P¼ 0.0186), DDD group (P¼ 0.0031), and in the
combined group (P¼ 0.0004). AREG levels were statistically signiﬁ-
cantly elevated in the group of individuals with diagnosed DDD
(P¼ 0.0272) andmarginally signiﬁcant in total sample of the affected
individuals (P¼ 0.0628). However, no statistically signiﬁcant differ-
ences between the controls and individuals with OAwere observed.
Table II shows pairwise phenotypic correlations between the
studied biochemical markers. All pairwise correlations were
substantial and statistically signiﬁcant, except the correlation
between AREG and EGFR, which, contradicting our expectations
was not signiﬁcant. Particularly interesting and signiﬁcant corre-
lation was observed between AREG and FRACT (r¼ 0.547,
P¼ 0.0001 in the total sample). The strength of the respective
correlations was comparable between the sexes. Also the magni-
tude of the correlations between AREG, FRACT and MCP-1 was
substantial and comparable between the sexes.
Quantitative genetic analysis
For both AREG and FRACT we observed statistically highly
signiﬁcant correlations between the parents and offspring (Fig. 2),
suggesting involvement of the genetic factors in variability of both
phenotypes.
To assess the magnitude of relative contribution of genetic and
common family environment factors to interindividual variability
of AREG and FRACT plasma levels, we conducted variance compo-
nents analysis for both biochemical markers. The analyses were
carried out on the log-transformed data with age and sex included
as covariates in the respective models. Table III shows the summary
of the variance component analysis, i.e., general models and MPMs.
The LRTs and the corresponding MPMs suggested a statistically
signiﬁcant effect of sex on the variation of FRACT and of age on
AREG concentration. The additive genetic component explained
29.68% of the variation of the AREG and 41.68% of the FRACT
circulatory levels, respectively. Contribution of common family
environment was negligible by LRT criteria.
We next examined whether the observed phenotypic correla-
tions among AREG, FRACT, and MCP-1 were caused by the sharedTable II
Phenotypic correlations, r and 95% conﬁdence interval (CI), between the circulating
levels of the studied biochemical markers. Correlations in males are above and in
females e below the diagonal
Marker MCP-1 FRACT AREG EGFR







N 449 444 448
P value 0.0001 0.0001 0.019







N 424 458 460
P value 0.0001 0.0001 0.029







N 417 439 467
P value 0.0001 0.0001 0.306







N 418 440 446
P value 0.548 0.408 0.622
Fig. 2. Mid-Parent e Offspring correlations for log-transformed and standardized AREG and FRACT plasma levels. AREG (Offspring)¼ 0.0659þ 0.2397 AREG (Mid-Parent);
FRACT(Offspring)¼ 0.0177þ 0.2953 FRACT (Mid-Parent). The data on circulating levels of each of the biomarkers, including AREG and FRACT, were log-transformed to achieve
normality of the distribution, and then were standardized for the sample mean (z-standardization).
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component analysis. Parameter estimates obtained in the univar-
iate MPMs were introduced as the starting parameter estimates in
the bivariate general models. Table IV shows the summary of the
bivariate analyses, i.e., RAD and RRS estimates as obtained in
the corresponding best ﬁtting and MPMs. By LRT, for each pair of
the compared biomarkers, statistically signiﬁcant genetic and
environmental correlations were observed. The highest values of
both RAD and RRS were found between AREG and FRACT, i.e., 0.5143
and 0.5731, respectively (Table IV). This means that common
genetic and environmental factors contribute substantially to the
observed phenotypic correlation.
Using the obtained estimates of RAD and RRS and implementing
quantitative genetics theory21, we next evaluated two additional
characteristics of the phenotypic covariation of AREG and FRACT.
First, we calculated to what extent the observed phenotypic
correlation was caused by overlapping genetic factors: VG%¼Table III
Summary of variance component analysis of AREG and FRACT levels in the study
sample
Parameter AREG FRACT
General MPM General MPM
Variance components
VAD 0.2993 0.2947 0.0816 0.4361 0.4039 0.0746
VSP 0.0163 (F) 0 0.0564 (F) 0
VHS 0 (F) 0 1.0E-10 (F) 0
VS1B 0.0065 (F) 0 0 (F) 0
VRS 0.6681 0.6981 0.0783 0.5027 0.5891 0.0649
Linear regression parameters
a0m 0.0431 (F) 0 0.1287 0.1290 0.0516
a0f 0.0530 (F) 0 0.1247 0.1298 0.0523
b1m 0.0264 0.0564 0.0305 0.0064 (F) 0
b1f 0.0918 ¼ b1m¼0.0564 0.0495 (F) 0
Likelihood of the models & models comparison
LH 1266.49 1268.44 1237.66 1239.67
LRT X2 3.9 X2 4.02
df 5 df 5
P 0.5639 P 0.5465
VAD e additive genetic component; VSPe common spouse environment component;
VHS e common household environment component; VSIB e common siblings’ envi-
ronment component and VRSe residual variance component. a0 is themean formales
and females; b is the sex speciﬁc regression coefﬁcient reﬂecting covariate age effect.
LH e likelihood; LRT – likelihood ratio test; df - degree of freedom; MPM – most
parsimonious model.100(RAD(X,Y)hXhY)/RPH¼ 33.0%. Similarly, the contribution due to
the shared environmental correlation (67.0%) was obtained.
Second, we partitioned the heritability estimate for each biomarker
into a component caused by common genes ½h2CðXÞ ¼ ðhXRADðX;YÞÞ2
and biomarker speciﬁc genetic effects, h2SðXÞ ¼ h2X  h2CðXÞ. The
corresponding h2C estimates were 0.0785 and 0.116 for AREG and
FRACT, respectively. Correspondingly only 26.2% and 26.4% of the
respective genetic effects were caused by shared genetic factors.
Discussion
A growing body of evidence suggests important roles for AREG
and FRACT in both normal and pathological processes, including
RA. The current data suggest that these molecules may also be
relevant for OA and DDD in a community-based sample (Fig. 1).
Despite the potential of these two molecules to serve as
biochemical markers and/or therapeutical targets in the context of
such clinical conditions as cancer, autoimmune diseases, osteopo-
rosis, and joint degeneration, little progress has been made in
characterization of genetic and environmental sources of AREG and
FRACT variability. Using the sample of ethnically homogeneous
nuclear families this study addressed several important aspects
required for understanding of the molecular processes involving
these factors as well for the efﬁcient use of these molecules in
research and clinical practice.
We ﬁrst investigated whether the growth factor AREG and the
cytokine FRACT may also play interrelated roles in progression of
joint degenerative disorders, which were of particular interest to
us. We divided our sample into the affected group comprised of
individuals for whom arthropathies were recorded, and the control
group (Fig. 1). Statistically signiﬁcant differences were observed in
FRACT levels between the controls and those with diagnosed
arthropathies (P¼ 0.0004), and speciﬁcally, in individuals affected
by OA (P¼ 0.0186) and DDD (P¼ 0.0031). Additionally, plasma
levels of AREG tended to be higher in the subgroup of DDDTable IV
Summary of bivariate variance component analysis of AREG, FRACT and MCP-1. RAD
and RRS are shown as estimated in the best ﬁtting and MPMs
AREG and FRACT AREG and MCP-1 FRACT and MCP-1
RAD 0.5143 0.0966 0.2877 0.1126 0.2787 0.0937
RRS 0.5731 0.0471 0.4158 0.0889 0.5051 0.0883
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results are in accord with the studies that observed statistically
signiﬁcantly elevated plasma concentrations of AREG and of FRACT
in synovial ﬂuid of RA patients8,13, and imply that both molecules,
but in particular FRACT has a potential to serve as biochemical
marker of joint pathologies.
Recent studies of the synovial ﬁbroblasts’ biology suggest a direct
mechanism underlying the observed phenotypic relationship
between FRACT levels and the status with respect to joint degener-
ative disorders. Thus, ﬁbroblasts were shown to be one of the
immediate targets of FRACT24. These cells represent an important
component of the synovium and have been shown to contribute to
joint destruction through the release of proinﬂammatory cytokines,
as well as the release of MMPs25e27. In turn, FRACT acts as a che-
moattractant for ﬁbroblasts in synovium and induces several
signaling pathways in this cell type via the MAP kinases p38, c-jun
N-terminal kinase (JNK) and extracellular signal-regulated kinase
(ERK) 1/2, as well as serine/threonine protein kinase (Akt)24.
Based on the published data suggesting that both these
biochemical factors maybe associated with developing joint syno-
vitis and our below reported ﬁndings, we assumed that the corre-
lation is possible between them and two other relevant molecules
i.e., EGFR and MCP-1 as mentioned in the Introduction. Indeed
relatively high and highly signiﬁcant correlation was observed
between AREG and FRACT (r¼ 0.55), which was of similar magni-
tude in males and females. The other two notable correlations were
between AREG andMCP-1 (r¼ 0.27), and between FRACT andMCP-
1 (r¼ 0.28). These ﬁndings imply a possibility of common signaling
pathways involving AREG, FRACT, and MCP-1, and indirectly
conﬁrmed in statistically signiﬁcant genetic and environmental
correlations between them (Table IV).
To our knowledge this study is the ﬁrst to investigate familial
aggregation of the AREG and FRACT circulating levels variation. It
shows that putative genetic factors constituted the main familial
source of the interindividual differences of the AREG and FRACT
levels in our sample, ranging from 29.68 8.22% to 41.68 7.51%,
respectively. These estimates are in agreement with heritability
estimates obtained for other biochemical markers previously
related to OA28. For example, heritability of cartilage oligomeric
matrix protein levels was estimated as 40%29, while the heritability
of C-reactive protein and interleukin-6 were 22% and 61%,
respectively30.
Our data also suggested that phenotypic correlations observed
between AREG, FRACT and MCP-1, are caused by both common
genetic factors and shared environment. The particularly high
bivariate heritability was observed between AREG and FRACT, i.e.,
common genetic factors accounted for 33% of the phenotypic
correlation between AREG and FRACT, and the rest was caused by
environmental factors simultaneously affecting plasma levels of
these molecules. Such considerable shared genetic and environ-
mental effects provide further evidence of the hypothesized func-
tional link among the selectedmarkers, and raise the questionwhat
are the speciﬁc sources of these genetic and environmental
correlations.
This study is not free from limitations. The major one concerns
clinical deﬁnitions and diagnostic criteria for assessment of the
idiopathic OA severity and lumbar degenerative disc disease (LDD),
speciﬁcally for each individual in the “case” group. This limitation
also includes combining participants with OA diagnosed at
different skeletal joints into a single group, whichwas primarily the
result of a low number of cases with the speciﬁc OA categories.
Clearly, the present results should be taken with caution and
considered as a pilot study. Another limitation is that a number of
confounding factors, such as diet, physical activity and life style,
potentially affecting AREG and FRACT plasma concentration, werenot considered. This opens up opportunities for further extensions
of the present study and motivates research of the functionally
relevant genes and potentially important environmental factors,
such as, for example, nutrition.
In conclusion, the present study has a number of novel ﬁndings.
It shows a statistically signiﬁcant association of circulating FRACT
levels with OA as well as with DDD. The latter had signiﬁcantly
elevated levels of AREG too. This paper is the ﬁrst to report statis-
tically signiﬁcant contribution of the genetic and familial factors to
the AREG and FRACT plasma levels variation in a community-based
sample of apparently healthy individuals. This ﬁnding motivates
further investigation of speciﬁc genetic and environmental factors
responsible for the observed effects which should improve our
understanding of the mechanisms determining plasma levels of
these two biochemical factors. Moreover, we found substantial
phenotypic, genetic and environmental correlation among AREG,
FRACTandMCP-1, which suggests common regulatorymechanisms
and physiological functions for these molecules. Conﬁrmation of
the association of AREG and especially FRACT with OA, as well as
clariﬁcation of its molecular-genetic mechanism is an imperative
next step in this research project.
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